Compare ROCK & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ROCK | INBX |
|---|---|---|
| Founded | 1972 | 2010 |
| Country | United States | United States |
| Employees | 2221 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 1996 | 2024 |
| Metric | ROCK | INBX |
|---|---|---|
| Price | $41.80 | $92.06 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $150.00 |
| AVG Volume (30 Days) | ★ 324.2K | 272.5K |
| Earning Date | 05-07-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,135,501,000.00 | $1,300,000.00 |
| Revenue This Year | $41.26 | N/A |
| Revenue Next Year | $20.14 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $33.56 | $13.97 |
| 52 Week High | $75.08 | $155.29 |
| Indicator | ROCK | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 59.33 | 41.99 |
| Support Level | $37.77 | $71.31 |
| Resistance Level | $42.73 | $94.52 |
| Average True Range (ATR) | 1.76 | 6.37 |
| MACD | 0.42 | 0.01 |
| Stochastic Oscillator | 78.04 | 30.95 |
Gibraltar Industries Inc manufactures and provides products and services for the Renewable energy, Residential, Agtech, and Infrastructure markets. The Renewable Segment is engaged in designing, engineering, manufacturing, and installing solar racking and electrical balance systems. Agtech Segment provides growing and processing solutions including the designing, engineering, manufacturing, full-scope construction, maintenance, and support of greenhouses and indoor growing operations, and botanical extraction systems. It derives key revenue from the Residential segment which offers roof and foundation ventilation products, single point and centralized mail systems electronic package solutions, and Retractable awnings and gutter guards, among other products.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.